Le Lézard
Classified in: Health, Business
Subjects: ERN, CCA, TRI

TapImmune Provides Third Quarter 2017 Corporate and Clinical Update


JACKSONVILLE, Fla., Nov. 15, 2017 /PRNewswire/ --

TapImmune, Inc. logo

Recent Corporate and Clinical Developments:

Upcoming Anticipated Milestones:

TapImmune Inc. (NASDAQ: TPIV), a leading clinical-stage immuno-oncology company with ongoing clinical trials in ovarian and breast cancer, today provided its business update for the third quarter 2017. A public conference call and live audio webcast is scheduled for today at 4:30 p.m. ET.

"TapImmune continued to advance its clinical and preclinical programs in the third quarter, which I believe positions us very well to achieve a number of important milestones in 2017 and beyond," said Peter Hoang, President and CEO of TapImmune. "I believe TapImmune is well positioned to advance immuno-oncology with its broadly effective cancer vaccine candidates and proprietary technologies in the indications and treatment settings we are targeting.  Having joined the company in late September, I was drawn to TapImmune because I see an opportunity to lead our industry, in translating the promise of cancer immunotherapy into potentially life-changing therapeutic outcomes.

"As we continue to advance our deep clinical pipeline, I am determined to drive TapImmune to its full potential. Our primary objective is to continue executing on our active Phase 2 trials as efficiently as possible.  We and our clinical partners also expect to launch additional clinical studies for each of our novel cancer vaccine candidates in order to further highlight their potential and generate even more value for the company. I believe that driving clinical execution should lead to several significant catalysts for the company and its shareholders over the coming quarters and years. I expect to drive efficiencies from an operational, regulatory and commercial standpoint, so that we achieve every milestone we set for the company.  In parallel, my goal is to drive enhanced appreciation and support for TapImmune by the investor community.  Finally, I intend to pursue opportunities to bolster our pipeline through strategic corporate and business development initiatives, in an effort to further expand the market opportunity for TapImmune."

Current Clinical Studies:

TPIV200: Lead T-cell vaccine targeting folate receptor alpha

Planned Clinical Studies:

TPIV200:

TPIV100/110 T-cell vaccine targeting HER2/neu:

Conference Call and Webcast Information:
The company will host a conference call and live audio webcast today, November 15, 2017, at 4:30 p.m. ET. Interested participants and investors may access the conference call by dialing either:

An audio webcast will be accessible via the New and Events section of the TapImmune website http://tapimmune.com/events/. An archive of the webcast and presentation will remain available for 90 days beginning at approximately 6:30 p.m. ET, on November 15, 2017.

About TapImmune Inc.
TapImmune Inc. is a leader in the development of novel immunotherapies for cancer, with multiple Phase 2 and Phase 1b/2 clinical studies currently ongoing for the treatment of ovarian and breast cancer. The company's peptide- or nucleic acid-based immunotherapeutic products comprise multiple naturally processed epitopes (NPEs) designed to comprehensively stimulate a patient's killer T cells and helper T cells, and to restore or further augment antigen presentation by using proprietary nucleic acid-based expression systems. This unique approach can produce off-the-shelf T-cell vaccine candidates that elicit a broad-based T-cell response and can be given without respect to HLA type. The company's technologies may be used as stand-alone medications or in combination with other treatment modalities.

For additional information, please visit: https://tapimmune.com/

To receive future press releases via email, please visit: https://tapimmune.com/investors/email-alerts/

Follow us on Twitter @Tapimmune_Inc, or follow us on Facebook.

For answers to frequently asked questions, please visit our FAQs page: https://tapimmune.com/investors/frequently-asked-questions/

Forward-Looking Statement Disclaimer
This release contains forward-looking information within the meaning of the Private Securities Litigation Reform Act of 1995. Statements in this news release concerning the Company's expectations, plans, business outlook or future performance, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are "forward-looking statements". Forward-looking statements are by their nature subject to risks, uncertainties and other factors which could cause actual results to differ materially from those stored in such statements. Such risks, uncertainties and factors include, but are not limited to the results of the Phase II clinical trials, the ability to obtain regulatory approval of TPIV200, the Company's ability to raise future financing for continued development and the ability to successfully commercialize TPIV200 as well as the risks and uncertainties set forth in the Company's most recent Form 10-K, 10-Q and other SEC filings which are available through EDGAR at www.sec.gov. The Company assumes no obligation to update the forward-looking statements.

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Unaudited)



Three Months Ended


Nine Months Ended


September 30,


September 30,


2017


2016


2017


2016

Operating expenses:








Research and development

$     1,623,302


$     1,109,332


$     3,815,119


$     3,343,248

General and administrative

2,549,272


1,612,305


5,167,582


3,557,701

Total operating expenses

4,172,574


2,721,637


8,982,701


6,900,949

Loss from operations

(4,172,574)


(2,721,637)


(8,982,701)


(6,900,949)

Other income (expense):








Change in fair value of warrant liabilities

4,000


684,000


8,500


5,925,000

Debt extinguishment gain

-


-


492,365


-

Grant income

183,064


-


183,064


231,200

Loss on debt settlement agreements

-


(65,325)


-


(135,640)

Other income  

-


-


-


1,828

Net loss

$   (3,985,510)


$   (2,102,962)


$   (8,298,772)


$     (878,561)









Basic net loss per share

$           (0.39)


$           (0.29)


$           (0.91)


$           (0.14)

Diluted net loss per share

$           (0.39)


$           (0.29)


$           (0.91)


$           (0.54)









Weighted average number of common shares outstanding, basic

10,219,138


7,281,000


9,081,678


6,370,000

Weighted average number of common shares outstanding, diluted

10,219,138


7,281,000


9,081,678


6,935,000

 

TAPIMMUNE INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(Unaudited)



September 30,


December 31,

2017


2016

ASSETS




Current assets:




Cash

$     7,607,735


$     7,851,243

Prepaid expenses and deposits

96,530


70,149

Total current assets

7,704,265


7,921,392

Total assets

$     7,704,265


$     7,921,392





LIABILITIES AND STOCKHOLDERS' EQUITY




Current liabilities:




Accounts payable and accrued liabilities

$     1,757,062


$     1,224,940

Research agreement obligations

-


492,365

Warrant liability

6,000


14,500

Promissory note

5,000


5,000

Total current liabilities

1,768,062


1,736,805

Total liabilities

1,768,062


1,736,805





COMMITMENTS AND CONTINGENCIES

-


-





Stockholders' equity:




Preferred stock - $0.001 par value, 5 million shares authorized at September 30, 2017 and December 31, 2016, respectively




Series A, $0.001 par value, 1.25 million shares designated, 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively

-


-

Series B, $0.001 par value, 1.5 million shares designated, 0 shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively

-


-

Common stock, $0.001 par value, 41.7 million shares authorized, 10.5 million and 8.4 million shares issued and outstanding as of September 30, 2017 and December 31, 2016, respectively

10,539


8,421

Additional paid-in capital

160,662,286


151,991,974

Accumulated deficit

(154,736,622)


(145,815,808)

Total stockholders' equity

5,936,203


6,184,587

Total liabilities and stockholders' equity

$     7,704,265


$     7,921,392

 

TAPIMMUNE INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(Unaudited)



Nine Months Ended


September 30,


2017


2016

Cash Flows from Operating Activities:




Net loss

$      (8,298,772)


$          (878,561)

Reconciliation of net loss to net cash used in operating activities:




Changes in fair value of warrant liabilities

(8,500)


(5,925,000)

Shares issued in debt settlement agreements

-


70,315

Stock-based compensation

2,332,915


1,309,109

Debt extinguishment gain

(492,365)


-

Changes in operating assets and liabilities:




Prepaid expenses and deposits

(26,381)


(42,849)

Accounts payable and accrued expenses

532,122


710,720

Net cash used in operating activities

(5,960,981)


(4,756,266)

Cash Flows from Financing Activities:




Proceeds from issuance of common stock and warrants in private placement, net of offering costs

5,408,343


2,331,126

Proceeds from exercise of stock warrants, net of offering costs

619,623


5,483,349

Repayment of promissory note

-


(25,000)

Repayment of promissory note - related party

-


(23,000)

Repurchase of common stock to pay for employee withholding taxes

(310,493)


-

Net cash provided by financing activities

5,717,473


7,766,475

Net (decrease) increase in cash

(243,508)


3,010,209





Cash at beginning of period

7,851,243


6,576,564

Cash at end of period

$         7,607,735


$         9,586,773

 

SOURCE TapImmune Inc.


These press releases may also interest you

at 09:10
BioSkryb Genomics, a company ushering in the next generation of single-cell technology, will highlight how its ResolveDNA and ResolveOME single-cell assays can unravel the complexities of tumor evolution at the American Association for Cancer...

at 09:07
KURU® Footwear, the inventor of heel-first footwear, today unveiled its 2024 Foot Pain Trends Report. Featuring significant industry discoveries and valuable consumer perspectives, KURU's comprehensive and medically reviewed report highlights the...

at 09:05
Personalis, Inc. , a leader in advanced genomics for precision oncology, announced today that a podium talk and multiple abstracts featuring data for the company's NeXT Personal® whole genome-based, tumor-informed assay for ultra-sensitive ctDNA...

at 09:05
...

at 09:04
Canadian-based Noze, a global leader in the breath-based diagnostic space, announced today it received a new grant from the Bill & Melinda Gates Foundation, bringing the foundation's total grant funding to Noze to $1.8 million. The announcement comes...

at 09:00
Headlands Research, a leading multinational network of clinical trial sites, today announced a fifth site, Headlands Research Orlando, as part of its partnership with Pfizer to create multiple clinical trial sites in areas with highly diverse...



News published on and distributed by: